- A Generational Opportunity in a $248B Market
Investor Relations
Delivering 70x superior pathogen reduction in a $248B market, Illumisoft combines a validated IP moat with an attractive valuation gap against legacy competitors to redefine global biological safety.
Exchange
TSX-V: UVC
Share Price
$0.30 CAD
- +7.14%
Market Cap
$10.7M
Valuation
$6.7M Pre
- Why Invest
Investment Highlights
Four compelling reasons why Illumisoft represents a unique investment opportunity in the infection prevention space.
1
The Market Arbitrage
Valuation & Upside Potential
$248B
Market 2024
$473B
Market 2034
9.9%
HAI CAGR
2
IP & Clinical Validation
The Technological Moat
Our portfolio is defended by 19+ patents. University of Leeds validated as “best performing UV device tested.” Our breakthrough Far-UVC technology is validated to be 70x more powerful in pathogen reduction while remaining safe for human occupancy.
19+
Patents
99.7%
Kill Rate
70x
More Powerful
3
The Execution Engine
Business Model & Regulatory
We hold the First Health Canada Registration for an upper-room GUV device. This regulatory first-mover advantage streamlines our path to FDA 510(k) and CE Marking while achieving 60% gross margins.
60%
Gross Margin
24
Day Payback
1st
HC Approval
4
Path to Liquidity
Roadmap & Catalysts
Phase 1 commercialization targets 6,500 hospitals in North America. Key catalysts include TSX-V listing, Tier-1 hospital contracts, and FDA 510(k) filing. Establishing Far-UVC as critical building infrastructure.
$248B
Market 2024
$473B
Market 2024
9.9%
Market 2024
- Market Size
Massive Market Opportunity
The global infection control market is experiencing unprecedented growth, driven by regulatory changes and heightened awareness of indoor air quality.
$248B
$473B
$38.5B
6.7%
- The Opportunity
Canada's Healthcare-Acquired Infection Crisis
Canada has the worst HAI rate in the OECD at 10.5% vs. 3% best practice. The consequences are catastrophic: 4,000+ deaths in Ontario LTC facilities alone, over $1 billion in combined lawsuits, and $29.3B in annual costs.
Canada responded by becoming the first nation to mandate engineered infection prevention standards through CSA Z8000:24 and CSA Z317.12:25.
Illumisoft is the only Canadian company with Health Canada-registered technology positioned to capture this market.
473,590
Annual HAIs in Canada
33,151
$29.3B
44,741%
- Share Structure
Capital Structure
Share Issuances:
• Acquisition of Illumisoft Lighting Inc.: 6,700,000 shares
• Acquisition of Equipment: 5,345,142 shares (36-month release)
• Acquisition of IP: 5,866,663 shares (24-month release)
Description
Shares
Common Shares*
22,261,805
CPC Shares (5:1 Consolidated)
1,881,667
Financing ($3.5M @ $0.30)
11,666,666
Warrants
0
Options
0
Fully Diluted
35,810,138
Pro-Forma Market Cap
35,810,138
- Why We Win
Competitive Advantages
SaniLux delivers 70x the pathogen elimination power of excimer-based alternatives at one-third the cost.
70x Faster Kill Speed
1/3 the Cost
Owned IP
- Backed By Visionaries
Strategic Investors
Mission-aligned investors committed to transforming global public health through breakthrough technology.
The pandemic exposed the critical need for effective indoor air disinfection. Illumisoft’s technology represents a real breakthrough that could fundamentally change how we protect indoor spaces.
Far-UVC is one of the most important public health innovations of our time. Illumisoft is leading the charge with technology that makes practical what was previously impossible.
19.9%
Resilience Reserve LLC
- Why Invest
Investor Documents
Access our latest investor materials, financial reports, and corporate documents.